Article

Novel compound shows promise for dry eye in proof-of-concept study

Author(s):

Julianne Mobilian
Conferences|ASCRS

Topical drug for the treatment of dry eye disease sees potential 

Eric D. Donnenfeld, MD, FAAO, shares results from an ex-U.S. proof-of-concept study investigating a novel, small peptide anti-integrin topical therapy (ALG-1007, Allegro Ophthalmics) for the treatment of dry eye disease. He presented his research at the 2019 annual ASCRS meeting in San Diego.

RELATED: Sustained-release implant promising for long-term IOP reduction

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
At the 2025 American Society of Cataract and Refractive Surgery (ASCRS) meeting, Seth Pantanelli, MD, speaks about the EyHance and enVista IOLs. Dr. Pantanelli is a professor of ophthalmology at Penn State College of Medicine in Hershey, Pennsylvania.
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
Related Content
(Image credit: AdobeStock/zinkevych) FDA nod for acoltremon: What its approval means for clinicians and patients
June 7th 2025

FDA nod for acoltremon: What its approval means for clinicians and patients

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)

Bausch + Lomb launches Blink Nourish Lubricating and Blink Boost Lubricating eye drops in US
June 6th 2025

Bausch + Lomb launches Blink Nourish Lubricating and Blink Boost Lubricating eye drops in US

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)

Iolyx Therapeutics reports phase 2 results for ILYX-002 in autoimmune-associated dry eye disease
May 27th 2025

Iolyx Therapeutics reports phase 2 results for ILYX-002 in autoimmune-associated dry eye disease

(Image credit: AdobeStock/frender) Q&A: Brandon D. Ayres, MD, on streamlining anterior vitrectomy with a high-speed, small-gauge probe at ASCRS 2025
May 26th 2025

Q&A: Brandon D. Ayres, MD, on streamlining anterior vitrectomy with a high-speed, small-gauge probe at ASCRS 2025

© 2025 MJH Life Sciences

All rights reserved.